Barclays analyst Kristen Stewart maintained a Sell rating on Edwards Lifesciences (EW) yesterday and set a price target of $155.00. The company’s shares closed last Friday at $223.48.
According to TipRanks.com, Stewart is a 3-star analyst with an average return of 1.8% and a 62.6% success rate. Stewart covers the Healthcare sector, focusing on stocks such as Zimmer Biomet Holdings, Baxter International, and Boston Scientific.
Edwards Lifesciences has an analyst consensus of Moderate Buy, with a price target consensus of $245.75.
See today’s analyst top recommended stocks >>
Based on Edwards Lifesciences’ latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $1.17 billion and net profit of $280 million. In comparison, last year the company earned revenue of $978 million and had a net profit of $7 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Edwards Lifesciences Corp. engages in the patient-focused medical innovations for heart disease and critical care monitoring. Its products are categorized into three areas: Transcatheter Heart Valves, Surgical Structural Heart and Critical Care. The Transcatheter Heart Valves portfolio includes technologies designed to treat heart valve disease using catheter-based approaches as opposed to open surgical techniques. Its portfolio includes technologies designed for nonsurgical replacement of heart valves. The Surgical Structural Heart portfolio includes tissue heart valves and heart valve repair products for the surgical replacement or repair of a patient’s heart valve. The Critical Care portfolio products through hemodynamic monitoring system measures a patient’s heart function and fluid status in surgical and intensive care settings. The company was founded by Miles Lowell Edwards in 1958 and is headquartered in Irvine, CA.
